The story of Viagra and its originator, copyright, presents a tangled picture for potential investors. While the revolutionary drug initially generated enormous earnings, its exclusivity has expired , leading to generic alternatives flooding the arena. This reduction in value presents a real challenge for copyright and any company considering a hea